Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.80 |
| ▸ | RAF1 | P04049 | 11/20 | 0.80 |
| ▸ | CSF1R | P07333 | 10/20 | 0.80 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.80 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.80 |
| ▸ | ARAF | P10398 | 1/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065842 | 0.92 | BRAF (0.83) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15066024 | 0.91 | BRAF (0.84) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15065801 | 0.91 | BRAF (0.87) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15067268 | 0.90 | BRAF (0.81) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15067385 | 0.90 | BRAF (0.85) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15066998 | 0.89 | BRAF (1.00) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL31061586 | 0.89 | BRAF (1.00) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL16303091 | 0.89 | BRAF (0.84) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL31406752 | 0.89 | BRAF (0.84) | BRAFRAF1CSF1RDDR2DDR1 | |
| SCHEMBL15067359 | 0.89 | BRAF (0.84) | BRAFRAF1CSF1RDDR2DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797927-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM IND CO LTD (KR) | 2019-09-25 | — | — | EP | claimed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | claimed |
| US-9156852-B2 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO., LTD (KR) | 2015-10-13 | — | — | US | claimed |
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM. CO., LTD (KR) | 2014-12-18 | — | — | US | claimed |
| EP-2797927-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | claimed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | claimed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| EP-3617213-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-2797927-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM IND CO LTD (KR) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| US-9156852-B2 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO., LTD (KR) | 2015-10-13 | — | — | US | disclosed |
| US-9156852-B2 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO., LTD (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM. CO., LTD (KR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM. CO., LTD (KR) | 2014-12-18 | — | — | US | disclosed |
| EP-2797927-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | TK1, DTYMK, MAP4K2 | BRAF 190/4885RAF1 148/4885CSF1R 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.